Hemodynamic effects of single-dose administration of AR-L 115 BS in patients with coronary artery disease.
2-[(2-Methoxy-4-methylsulfinyl)phenyl]-1H-imidazo[4,5-b]pyridine (AR-L 115 BS) was investigated in 14 patients with coronary artery disease (CAD) and an elevated left ventricular enddiastolic pressure at rest (LVEDP). There was a significant decrease in the systolic (AOPS) and diastolic aortic pressures (AOPD) of 9% and 6%, respectively, (p less than 0.001, p less than 0.01). The LVEDP decreased by 29% (p less than 0.001), and the maximum rate of pressure rise (dp/dt max) increased by 19% (p less 0.001). The systolic (PAPS) and diastolic pulmonary artery pressures (PAPD) fell by 17% and 16%, respectively (p less than 0.05). The cardiac index (CI) increased by 12% (p less than 0.05), and the peripheral resistance (SVR) fell by 17% (p less than 0.001). Heart rate increased slightly by 5% (p less than 0.1) but this was of no clinical relevance. The right atrial pressure (RAP) and the tension time index (TTI) remained unchanged. AR-L 15 BS was observed to have vasodilating and positive inotropic effects without increasing oxygen consumption. It can therefore be recommended for use in patients with CAD and an elevated LVEDP. Side-effects have not been reported.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D006328:Cardiac Catheterization; D002302:Cardiac Output / Q000187:drug effects; D002316:Cardiotonic Agents / Q000494:pharmacology*; D003327:Coronary Disease / Q000503:physiopathology*; D004562:Electrocardiography; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D002316:Cardiotonic Agents; D007093:Imidazoles; C029758:sulmazole